Oncaspar
Drug Oncology
NDC 0944-3810-01
General payments
$389,279
Research payments
$6,073,328
Through program year 2019, $389,279 in general payments and $6,073,328 in research payments were reported against Oncaspar (Oncology).
No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.
By program year
2 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2019 | General | $389,279 | 895 |
| 2019 | Research | $6,073,328 | 19 |
Breakdown
The top 5 of the 100 largest recipients; each share is of general payments naming this product in 2019.
The top 5 of 29 specialties; each share is of general payments naming this product to practitioners with a specialty in 2019. Each practitioner is counted under their primary specialty.
The top 5 of 37 states; each share is of general payments naming this product in 2019 where a state was reported.
Records
895 general · 19 researchEvery payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
What you are looking at
Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.